Inhibikase Therapeutics (IKT) Institutional Ownership $2.09 -0.10 (-4.57%) Closing price 04:00 PM EasternExtended Trading$2.10 +0.01 (+0.48%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)CurrentInstitutional OwnershipPercentage3.81%Number ofInstitutional Buyers(last 12 months)18TotalInstitutional Inflows(last 12 months)$77.71MNumber ofInstitutional Sellers(last 12 months)0 Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IKT Institutional Buying and Selling by Quarter Remove Ads Inhibikase Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/27/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/18/2025Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/17/2025Soleus Capital Management L.P.6,325,000$20.56M1.3%N/A9.119% 2/17/2025Squarepoint Ops LLC28,411$92K0.0%N/A0.041% 2/17/2025Stonepine Capital Management LLC1,132,388$3.68M3.0%N/A1.633% 2/17/2025OMERS ADMINISTRATION Corp54,600$177K0.0%N/A0.079% 2/17/2025Millennium Management LLC142,209$462K0.0%N/A0.205% 2/17/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/17/2025Fairmount Funds Management LLC6,125,000$19.91M2.0%N/A8.831% 2/17/2025Blackstone Inc.2,070,684$6.73M0.0%N/A2.985% Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025Caxton Corp16,393$53K0.3%N/A0.024% 2/14/2025Nantahala Capital Management LLC2,190,000$7.12M0.3%N/A3.157% 2/14/2025Northern Trust Corp64,011$208K0.0%N/A0.092% 2/14/2025Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/14/2025Stifel Financial Corp13,129$43K0.0%N/A0.019% 2/13/2025Barclays PLC84,000$273K0.0%N/A0.121% 2/13/2025ADAR1 Capital Management LLC5,103,005$16.59M3.3%N/A7.357% 2/12/2025Geode Capital Management LLC322,878$1.05M0.0%+544.9%0.466% 2/12/2025Blair William & Co. IL134,953$439K0.0%+7.0%0.195% 8/15/2024Armistice Capital LLC589,575$713K0.0%N/A8.170% 11/15/2023Armistice Capital LLC186,046$259K0.0%-62.5%3.477% 9/21/2023Barclays PLC11,455$41K0.0%N/A0.214% 8/8/2023Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266% 5/2/2023Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286% 2/10/2023Blair William & Co. IL229,000$114K0.0%+27.9%0.817% 7/12/2022Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259% 5/6/2022Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461% 5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476% 5/4/2022Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657% 5/3/2022Redmond Asset Management LLC122,682$182K0.1%N/A0.486% 2/14/2022Murchinson Ltd.220,947$327K0.0%-31.2%0.878% 2/8/2022Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586% 2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279% 11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019% 11/16/2021Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103% 11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202% 8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926% 8/16/2021Antara Capital LP250,000$700K0.0%N/A2.467% 8/16/2021Warberg Asset Management LLC90,000$252K0.0%N/A0.888% 8/16/2021Sabby Management LLC421,200$1.18M0.2%N/A4.157% Elon Tax Shock? (Ad)Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.Move now and you could get in first - with huge upside potential.8/13/2021Altium Capital Management LP109,749$307K0.1%N/A1.083% 8/13/2021Murchinson Ltd.320,947$899K0.3%N/A3.167% 8/13/2021Vanguard Group Inc.470,615$1.32M0.0%N/A4.644% 8/13/2021FMR LLC433,300$1.21M0.0%+333.3%4.276% 8/12/2021Kepos Capital LP700,000$1.96M0.1%N/A6.908% 5/21/2021Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/18/2021Millennium Management LLC11,224$67K0.0%N/A0.112% 5/18/2021Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/17/2021HRT Financial LP11,614$69K0.0%N/A0.115% (Data available from 1/1/2016 forward)Remove Ads IKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IKT shares? During the previous two years, 19 institutional investors and hedge funds held shares of Inhibikase Therapeutics. The most heavily invested institutionals were Soleus Capital Management L.P. ($20.56M), Fairmount Funds Management LLC ($19.91M), ADAR1 Capital Management LLC ($16.59M), Nantahala Capital Management LLC ($7.12M), Blackstone Inc. ($6.73M), Stonepine Capital Management LLC ($3.68M), and Geode Capital Management LLC ($1.05M).Learn more on IKT's institutional investors. What percentage of Inhibikase Therapeutics stock is owned by institutional investors? 3.81% of Inhibikase Therapeutics stock is owned by institutional investors. Learn more on IKT's institutional investor holdings. Which institutional investors have been buying Inhibikase Therapeutics stock? Of the 19 institutional investors that purchased Inhibikase Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Soleus Capital Management L.P. ($6.33M), Fairmount Funds Management LLC ($6.13M), ADAR1 Capital Management LLC ($5.10M), Nantahala Capital Management LLC ($2.19M), Blackstone Inc. ($2.07M), Stonepine Capital Management LLC ($1.13M), and Armistice Capital LLC ($589.58K). How much institutional buying is happening at Inhibikase Therapeutics? Institutional investors have bought a total of 24,373,607 shares in the last 24 months. This purchase volume represents approximately $78.28M in transactions. Which Inhibikase Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($310.50K), and Hamilton Lane Advisors LLC ($69.02K). How much institutional selling is happening at Inhibikase Therapeutics? Institutional investors have sold a total of 379,516 shares in the last 24 months. This volume of shares sold represents approximately $1.93M in transactions. Related Companies CRMD Major Shareholders IMNM Major Shareholders ABUS Major Shareholders BCYC Major Shareholders DNTH Major Shareholders KURA Major Shareholders CDXC Major Shareholders KALV Major Shareholders MGTX Major Shareholders VALN Major Shareholders This page (NYSE:IKT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
